0001104659-17-041905.txt : 20170627 0001104659-17-041905.hdr.sgml : 20170627 20170627215606 ACCESSION NUMBER: 0001104659-17-041905 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170623 FILED AS OF DATE: 20170627 DATE AS OF CHANGE: 20170627 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics Plc CENTRAL INDEX KEY: 0001703287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 6108166640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Plc DATE OF NAME CHANGE: 20170407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Khuong Chau Quang CENTRAL INDEX KEY: 0001609405 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38132 FILM NUMBER: 17933633 MAIL ADDRESS: STREET 1: C/O ORBIMED ADVISORS STREET 2: 601 LEXINGTON AVENUE, 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 4 1 a4.xml 4 X0306 4 2017-06-23 0 0001703287 Nabriva Therapeutics Plc NBRV 0001609405 Khuong Chau Quang 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 0 1 0 Ordinary Shares 2017-06-23 5 J 0 E 1677940 0 A 1677940 I See footnotes Ordinary Shares 2017-06-23 5 J 0 E 2241660 0 A 2241660 I See footnotes Stock Option 2017-06-23 5 J 0 E 10100 0 A 2026-08-25 Ordinary Shares 10100 10100 D Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. These shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC ("GP V"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. ("OPI V Cooperatief"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. ("OPI V- NB"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors. The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose. These shares are held of record by OPI V-NB. The exercise price is 6.634 Euro. This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017. /s/ Gary L. Sender, by power of attorney 2017-06-27